Evercore ISI Group Downgrades Legend Biotech to In-Line, Announces $20 Price Target
Is Legend Biotech (LEGN) Reasonable After CARVYKTI Sales Growth?
Oppenheimer Maintains Perform on Legend Biotech, Lowers Price Target to $25
Morgan Stanley Maintains Overweight on Legend Biotech, Lowers Price Target to $43
Barclays Maintains Overweight on Legend Biotech, Lowers Price Target to $61
RBC Capital Maintains Outperform on Legend Biotech, Lowers Price Target to $50
Legend Biotech (LEGN) Q3 2026 Earnings Call Transcript
Legend Biotech Corp (LEGN) Q3 2026 Earnings Call Highlights: CARVYKTI Sales Jump 36% as ...
LEGN Stock On Track For Worst Day Ever As Investors Focus On Decelerating US Demand For CARVYKTI Therapy
What Legend Biotech (LEGN) Said on Its Q3 Earnings Call
Legend Biotech Corporation (LEGN) Q3 2026 Earnings Call Transcript
Legend Biotech Reports Third Quarter 2026 Results and Recent Highlights
Legend Biotech Q3 2026 Earnings Call Transcript
Legend Biotech Q3 Adj. EPS $0.14 Beats $0.00 Estimate, Sales $359.500M Miss $361.619M Estimate
Legend Biotech to Showcase CARVYKTI® Leadership and Next-Generation Cell Therapy Innovation at ASH 2026
Legend Biotech Corporation Sponsored ADR (LEGN) Recently Broke Out Above the 200-Day Moving Average
Legend Biotech (LEGN) Stock Could Trade Below Its Sales Backdrop
Legend Biotech Corporation Sponsored ADR (LEGN) Crossed Above the 50-Day Moving Average: What That Means for Investors
Legend Biotech to Host Investor Conference Call on Third Quarter 2026 Results
Legend Biotech Announces U.S. FDA Clearance of IND Application for LB2501, an Investigational CD19/CD20 In Vivo CAR-T Therapy
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.